Last reviewed · How we verify
Afuresertib HPMC capsule - Fasted State — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Afuresertib HPMC capsule - Fasted State (Afuresertib HPMC capsule - Fasted State) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Afuresertib HPMC capsule - Fasted State TARGET | Afuresertib HPMC capsule - Fasted State | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Afuresertib HPMC capsule - Fasted State CI watch — RSS
- Afuresertib HPMC capsule - Fasted State CI watch — Atom
- Afuresertib HPMC capsule - Fasted State CI watch — JSON
- Afuresertib HPMC capsule - Fasted State alone — RSS
Cite this brief
Drug Landscape (2026). Afuresertib HPMC capsule - Fasted State — Competitive Intelligence Brief. https://druglandscape.com/ci/afuresertib-hpmc-capsule-fasted-state. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab